NeuroEM Therapeutics, a clinical-stage biotechnology company developing non-drug bioengineered approaches to cognitive decline and Alzheimer’s disease, announced the appointment of Dr. W. Scott Burgin, MD, as its first Chief Medical Officer (CMO).
Dr. Burgin has been a long-time medical advisor to NeuroEM prior to this role, and brings decades of experience in neurology, clinical care, research, administration and teaching to the company. His expertise includes stroke neurology, AI-driven innovations, biomarker development and intellectual property, and he has contributed to more than 75 clinical research projects and authored over 100 peer-reviewed scientific publications.
In his new position, Dr. Burgin will lead NeuroEM’s clinical strategy and research direction as the company advances its wearable, transcranial electromagnetic treatment (TEMT-RF) technology toward broader clinical application. This device—developed from research at the University of South Florida and backed by the FDA’s Breakthrough Device designation for Alzheimer’s disease—aims to address cognitive decline without drugs by modulating neuronal activity.
He will continue his academic work as a professor of neurology at a leading U.S. medical research institution, while helping strengthen NeuroEM’s translational research and clinical development efforts as CMO, bridging scientific innovation with clinical implementation.
